EUCTR2015-003622-13-PT进行中（未招募）1 期
BI 655066 (risankizumab) versus Ustekinumab and placebo comparators in a randomized double blind trIal for Maintenance use in Moderate to severe plaque type psoriasis-2 (UltIMMa-2) - BI 655066 pivotal efficacy trial with placebo and active comparator
nilfarma - União Internacional de Lab. Farmacêuticos, Lda0 个研究点目标入组 500 人开始时间: 2016年2月2日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male or female patients with age >= 18 years at screening,
- •Women of childbearing potential must be ready and able to use highly effective methods of birth control,
- •Have a diagnosis of chronic plaque psoriasis (with or without psoriatic arthritis) for at least 6 months before the first administration of study drug.
- •Have stable moderate to severe chronic plaque psoriasis with or without psoriatic arthritis at both Screening and Baseline (Randomization):
- •a.Have an involved body surface area (BSA) >= 10% and
- •b.Have a Psoriasis Area and Severity Index (PASI) score >= 12 and
- •c.Have a static Physician Global Assessment (sPGA) score of >= 3.
- •Must be candidates for systemic therapy or phototherapy for psoriasis treatment, as assessed by the investigator
- •Must be a candidate for treatment with Stelara® (ustekinumab) according to local label.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 425
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 75
排除标准
- •Patients with:
- •a. non-plaque forms of psoriasis (including guttate, erythrodermic, or pustular),
- •b. current drug-induced psoriasis (including an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium),
- •c. active ongoing inflammatory diseases other than psoriasis and psoriatic arthritis that might confound trial evaluations according to investigators judgment,
- •Previous exposure to BI 655066,
- •Previous exposure to ustekinumab (Stelara®),
- •Currently enrolled in another investigational study or less than 30 days (from screening) since completing another investigational study (participation in observational studies is permitted),
- •Use of any restricted medication , or any drug considered likely to interfere with the safe conduct of the study,
- •Major surgery performed within 12 weeks prior to randomization or planned within 12 months after screening (e.g. hip replacement, aneurysm removal, stomach ligation),
- •Known chronic or relevant acute infections including active tuberculosis, HIV or viral hepatitis,
- •Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening, except appropriately treated basal or squamous cell carcinoma of the skin or in situ carcinoma of uterine cervix,
- •Evidence of a current or previous disease, medical condition (including chronic alcohol or drug abuse) other than psoriasis, surgical procedure (i.e., organ transplant), medical examination finding (including vital signs and ECG), or laboratory value at the screening visit outside the reference range that is in the opinion of the investigator, is clinically significant and would make the study participant unreliable to adhere to the protocol or to complete the trial, compromise the safety of the patient, or compromise the quality of the data,
- •History of allergy/hypersensitivity to a systemically administered biologic agent or its excipients,
- •Women who is pregnant, nursing, or who plans to become pregnant while in the trial,
研究者
相似试验
进行中（未招募）
1 期
BI 655066 (risankizumab) compared to placebo and ustekinumab in patients with moderate to severe chronic plaque psoriasisPsoriasisMedDRA version: 20.0Level: PTClassification code 10037153Term: PsoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2015-003622-13-PLBoehringer Ingelheim Pharma GmbH & Co.KG500
进行中（未招募）
1 期
BI 655066 (risankinumab) compared to placebo and ustekinumab in patients with moderate to severe chronic plaque psoriasisEUCTR2015-003622-13-ITBOEHRINGER-INGELHEIM ITALIA S.P.A.577
进行中（未招募）
1 期
BI 655066/ABBV-066 (risankizumab) compared to placebo andactive comparator (ustekinumab) in patients with moderate tosevere chronic plaque psoriasisEUCTR2015-003622-13-DEBoehringer Ingelheim Pharma GmbH & Co. KG500
进行中（未招募）
1 期
BI 655066/ABBV-066 (risankizumab) compared to placebo andactive comparator (ustekinumab) in patients with moderate tosevere chronic plaque psoriasisPsoriasisEUCTR2014-005117-23-DEBoehringer Ingelheim Pharma GmbH & Co. KG500
进行中（未招募）
1 期
BI 655066/ABBV-066 (risankizumab) compared to placebo and active comparator (ustekinumab) in patients with moderate to severe chronic plaque psoriasisEUCTR2014-005117-23-CZBoehringer Ingelheim RCV GmbH & Co. KG500